MCID: UTR043
MIFTS: 33

Uterine Sarcoma malady

Categories: Rare diseases, Cancer diseases

Aliases & Classifications for Uterine Sarcoma

About this section

Aliases & Descriptions for Uterine Sarcoma:

Name: Uterine Sarcoma 45 47
Uterine Corpus Sarcoma 65
 
Sarcoma of the Uterus 45

Classifications:



Summaries for Uterine Sarcoma

About this section
Wikipedia:68 The uterine sarcomas form a group of malignant tumors that arises from the smooth muscle or connective... more...

MalaCards based summary: Uterine Sarcoma, also known as uterine corpus sarcoma, is related to breast cancer and inflammatory bowel disease 13. An important gene associated with Uterine Sarcoma is ABCB1 (ATP Binding Cassette Subfamily B Member 1), and among its related pathways are Methotrexate Pathway, Pharmacokinetics and Etoposide Pathway, Pharmacokinetics/Pharmacodynamics. Affiliated tissues include uterus, breast and smooth muscle, and related mouse phenotypes are tumorigenesis and digestive/alimentary.

Related Diseases for Uterine Sarcoma

About this section

Diseases related to Uterine Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 299)
idRelated DiseaseScoreTop Affiliating Genes
1breast cancer28.5ABCB1, ABCC1, CDK2, CYP19A1, ESR1, KIT
2inflammatory bowel disease 1310.5ABCB1, ABCC1
3penis basal cell carcinoma10.5ABCB1, ABCC1
4malignant breast melanoma10.5MCAM, WT1
5pancreatic ductal carcinoma10.5KIT, WT1
6spindle cell variant squamous cell breast carcinoma10.4DES, WT1
7anal gland neoplasm10.4SMARCB1, WT1
8ovarian papillary cystadenoma10.4DES, WT1
9apocrine sweat gland neoplasm10.4MDM2, PGRMC1
10sarcomatosis10.4ABCB1, MB
11malignant teratocarcinosarcoma10.3DES, KIT
12acantholytic squamous cell skin carcinoma10.3ABCB1, ABCC1, KIT
13olfactory nerve disease10.3ABCB1, KIT
14rapidly progressive glomerulonephritis10.3KIT, SMARCB1, WT1
15kidney rhabdoid cancer10.3DES, SMARCB1, WT1
16benign mesothelioma10.3DES, KIT
17congenital fibrosis of the extraocular muscles10.3DES, PDGFRB
18esophageal lipoma10.3DES, MDM2
19hypotrichosis 810.3ABCB1, ABCC1, KIT
20extragonadal nonseminomatous germ cell tumor10.3ESR1, KIT
21vulval paget's disease10.3ESR1, SMARCB1
22conventional fibrosarcoma10.2MB, WT1
23esophageal adenoid cystic carcinoma10.2ESR1, KIT
24median neuropathy10.2MDM2, SMARCB1, WT1
25external ear squamous cell carcinoma10.2KIT, MB
26osteogenesis imperfecta-retinopathy-seizures-intellectual disability syndrome10.2KIT, PDGFRB, WT1
27ovary epithelial cancer10.2ABCB1, ESR1, WT1
28ovarian wilms' cancer10.2ABCB1, ESR1, WT1
29nystagmus 3, congenital, autosomal dominant10.2ABCB1, ABCC1, MVP, WT1
30pulmonary plasma cell granuloma10.2MB, SMARCB1, WT1
31ovary leiomyosarcoma10.2KIT, MDM2, WT1
32germ cell and embryonal cancer10.2CDK2, MDM2, SMARCB1
33cellular schwannoma10.2DES, KIT, SMARCB1
34spindle cell liposarcoma10.2MB, MDM2
35staphyloenterotoxemia10.2MB, SMARCB1, WT1
36acute liver failure10.2ABCB1, KIT, WT1
37bone peripheral neuroepithelioma10.2MB, MDM2
38follicular basal cell carcinoma10.2ESR1, KIT
39pacinian tumor10.2MB, MDM2
40mixed liposarcoma10.2KIT, MDM2
41intravascular angioleiomyoma10.1CDK2, KIT, MB
42benign multicystic peritoneal mesothelioma10.1CYP19A1, DES
43lung leiomyosarcoma10.1DES, MB, WT1
44prostatitis10.1
45pancreatitis10.1
46mediastinum synovial sarcoma10.1KIT, MB, SMARCB1
47desmoplastic infantile astrocytoma10.1DES, KIT, PDGFRB
48male reproductive organ benign neoplasm10.1ESR1, KIT, SMARCB1
49autosomal dominant charcot-marie-tooth disease type 2a210.1DES, KIT, MDM2
50agammaglobulinemia 210.1ABCB1, KIT, PDGFRB, WT1

Graphical network of the top 20 diseases related to Uterine Sarcoma:



Diseases related to uterine sarcoma

Symptoms for Uterine Sarcoma

About this section

Drugs & Therapeutics for Uterine Sarcoma

About this section

Drugs for Uterine Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 195)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
GemcitabineapprovedPhase 3, Phase 2, Phase 1188195058-81-460750
Synonyms:
103882-84-4
122111-03-9
2',2'-DiF-dC
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-.beta.-D-2',2'-difluorocytidine
2'-Deoxy-2',2'-difluorocytidine
4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H-pyrimidin-2-one
4-amino-1-((2R,4R,5R)-3,3-Difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
95058-81-4
AB1004842
AC1L1TUQ
C07650
CCRIS 8984
CHEBI:175901
CHEMBL888
CID60750
Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine
D02368
DB00441
DDFC
DFDC
DFdC
DFdCyd
Folfugem
GEO
Gamcitabine
GemLip
Gemcel
 
Gemcin
Gemcitabin
Gemcitabina
Gemcitabina [INN-Spanish]
Gemcitabine
Gemcitabine (USAN/INN)
Gemcitabine HCl
Gemcitabine Hydrochloride
Gemcitabine hydrochloride
Gemcitabine stereoisomer
Gemcitabinum
Gemcitabinum [INN-Latin]
Gemtro
Gemzar
Gemzar (hydrochloride)
HMS2089P10
HSDB 7567
Inno-D07001
LS-59139
LY 188011
LY-188011
LY188011
NCGC00168784-01
NChemBio.2007.10-comp25
NSC 613327
NSC613327
TL8005979
UNII-B76N6SBZ8R
ZINC18279854
Zefei
gemcitabine
nchembio.573-comp7
nchembio.90-comp2
2
Epoetin alfaapprovedPhase 3626113427-24-0
Synonyms:
Epogen
 
Erythropoietin precursor
Procrit
3
Bevacizumabapproved, investigationalPhase 3, Phase 2, Phase 11875216974-75-3
Synonyms:
216974-75-3
Avastin
Avastin (TN)
Bevacizumab
Bevacizumab (genetical recombination)
 
Bevacizumab (genetical recombination) (JAN)
D06409
R-435
anti-VEGF monoclonal antibody
antiVEGF
bevacizumab
4
CisplatinapprovedPhase 3, Phase 2, Phase 1254015663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatin
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinol-aq
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
5
IfosfamideapprovedPhase 3, Phase 2, Phase 13713778-73-23690
Synonyms:
(+-)-Ifosfamid
(+-)-Ifosphamide
(+-)-Tetrahydro-N,3-bis(2-chloroethyl)-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
(D,L)-Ifosfamide
(R,S)-Ifosphamide
(R,S)-N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide
1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide
2,3-(N,N(sup 1)-Bis(2-chloroethyl)diamido)-1,3,2-oxazaphosphoridinoxyd
2,3-N,N(sup 1)-Bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxyd
2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis( 2-chloroethyl)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide (8CI)
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide
3,} 2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-((2-chloroethyl)amino)perhydro-2H-1,3,2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorineoxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2- oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
36341-88-5
3778-73-2
84711-20-6
A 4942
AB00513932
AC-2113
AC1L1GHW
ASTA Z 4942
Ambap3778-73-2
Asta Z 4942
BPBio1_000865
BRN 0611835
BSPBio_000785
C07047
CAS-3778-73-2
CCRIS 352
CHEBI:5864
CHEMBL1024
CID3690
Cyfos
D00343
D007069
DB01181
EINECS 223-237-3
HMS1570H07
HMS2090M12
HMS2093N07
HSDB 7023
Holoxan
Holoxan 1000
I-Phosphamide
I06-0494
IFEX (TN)
Ifex
Ifosfamid
Ifosfamida
Ifosfamida [INN-Spanish]
Ifosfamide
 
Ifosfamide (JAN/USP/INN)
Ifosfamide Sterile
Ifosfamide [USAN:INN:BAN:JAN]
Ifosfamidum
Ifosfamidum [INN-Latin]
Ifosphamide
Ifsofamide
Iphosphamid
Iphosphamid(e)
Iphosphamide
Iso Endoxan
Iso-Endoxan
Isoendoxan
Isofosfamide
Isophosphamide
Isosfamide
LS-102
LS-99799
MJF 9325
MJF-9325
MLS002154021
Mitoxana
Mitoxana, Ifex, Ifosfamide
MolPort-003-666-704
N,3-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
N,N-Bis(beta-chloroethyl)-amino-N',O-propylene-phosphoric acid ester diamide
N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid
N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid [German]
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylen ephosphoric acid diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylene phosphoric acid ester diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide
N-(2-Chloroethyl)-N-(3-(2-chloroethyl)-2-oxido-1,3,2-oxazaphosphinan-2-yl)amine
NCGC00016639-01
NCGC00179435-01
NCI-C01638
NCI60_000233
NPFAPI-04
NSC 109,724
NSC 109724
NSC-109,724
NSC-109724
NSC109,724
NSC109724
Naxamide
Prestwick0_000833
Prestwick1_000833
Prestwick2_000833
Prestwick3_000833
S1302_Selleck
SMR001233348
SPBio_002706
STL058690
UNII-UM20QQM95Y
WLN: T6NPOTJ AM2G BO B2G
Z 4942
Z-4942
Z4942
ifosfamide
isosfamide
{3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,
6
PaclitaxelapprovedPhase 3, Phase 2, Phase 1262133069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
7
MechlorethamineapprovedPhase 3, Phase 2, Phase 130951-75-24033
Synonyms:
.Beta.,.beta.'-Dichlorodiethyl-N-methylamine
1, 5-Dichloro-3-methyl-3-azapentane hydrochloride
126-85-2 (N-oxide)
2,2'-Dichloro-N-me
2,2'-Dichloro-N-methyldiethylamine
2,2'-Dichlorodiethyl-methylamine
2,2'-dichloro-N-methyldiethylamine
2-Chloro-N-(2-chloroethyl)-N-methylethanamine
302-70-5 (N-oxide, hydrochloride)
51-75-2
55-86-7 (HYDROCHLORIDE)
AC1L1H9H
Antimit
BRN 0605323
BSPBio_001947
Bis(2-chloroethyl)methylamine
Bis(beta-chloroethyl) methylamine
Bis(beta-chloroethyl)methylamine
C07115
C5H11Cl2N
CCRIS 447
CHEBI:28925
CHEMBL427
CID4033
Carolysine
Caryolysin
Caryolysine
Chloramine (the nitrogen mustard)
Chlorethazine
Chlormethine
Chlormethine (INN)
Chlormethine [INN:BAN]
Chlormethinum [INN-Latin]
Cloramin
Clormetina
Clormetina [INN-Spanish]
D07671
DB00888
Di(2-chloroethyl)methylamine
Dichlor amine
Dichloren
DivK1c_000759
EINECS 200-120-5
ENT-25294
Embechine
Embichin
HMS1920J15
HMS2091B04
HMS502F21
HN-2
HN2
HSDB 5083
I14-8708
IBS-L0033631
IDI1_000759
KBio1_000759
KBio2_001369
KBio2_003937
KBio2_006505
KBio3_001447
KBioGR_001448
 
KBioSS_001369
LS-7559
MBA
Me chloroethamine
Mebichloramine
Mechlorethamine
Mechlorethamine hydrochloride
Mechlorethanamine
Mechloroethamine
Mecloretamina
Mecloretamina [Italian]
Methylbis(2-chloroethyl)amine
Methylbis(beta-chloroethyl)amine
Methyldi(2-chloroethyl)amine
Mitoxine (*Hydrochloride*)
MolPort-001-785-592
Mustargen
Mustine
Mustine note
Mutagen
N,N-Bis(2-chloroethyl)-N-methylamine
N,N-Bis(2-chloroethyl)methylamine
N,N-Di(chloroethyl)methylamine
N-Lost
N-Methyl lost
N-Methyl-2,2'-dichlorodiethylamine
N-Methyl-bis(2-chloroethyl)amine
N-Methyl-bis(beta-chloroethyl)amine
N-Methyl-bis-chloraethylamin
N-Methyl-bis-chloraethylamin [German]
N-Methyl-lost
N-Methyl-lost [German]
N-methyl-bis(2-chloroethyl)amine
NCGC00091835-02
NCGC00091835-03
NCGC00091835-04
NCGC00091835-05
NCI60_041682
NINDS_000759
NSC762
Nitol (*Hydrochloride*)
Nitrogen mustard
Nitrogen mustard (HN-2)
Nitrogranulogen
SPBio_000496
SPECTRUM1500375
Spectrum2_000448
Spectrum3_000484
Spectrum4_000924
Spectrum5_001702
Spectrum_000889
Stickstofflost (*Hydrochloride*)
Stickstofflost (ebewe)
T 1024
T-1024
TL 146
UNII-50D9XSG0VR
Valchlor
beta,Beta'-dichlorodiethyl-N-methylamine
beta,beta'-Dichlorodiethyl-N-methylamine
mechlorethamine
thyldiethylamine
β,β'-dichlorodiethyl-N-methylamine
8
Fentanylapproved, illicit, investigationalPhase 3705437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Abstral
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl - Novaplus
Fentanyl Citrate
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
 
Fentanyl-12
Fentanyl-25
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Lazanda
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
Subsys
UNII-UF599785JZ
fentanyl
9
Methylphenidateapproved, investigationalPhase 3364113-45-14158
Synonyms:
.alpha.-Phenyl-2-piperidineacetic acid methyl ester
113-45-1
2-Piperidineacetic acid, .alpha.-phenyl-, methyl ester
2-Piperidineacetic acid, alpha-phenyl-, methyl ester
298-59-9 (hydrochloride)
4311/B Ciba
AC1L1HJM
C 4311
C07196
CHEBI:6887
CHEMBL796
CID4158
Calocain
Centedein
Centedrin
Centedrine
Centredin
Concerta
D-Methylphenidate HCl
D04999
DB00422
DB06701
DEA No. 1724
Daytrana
Daytrana (TN)
EINECS 204-028-6
Focalin
Focalin XR
HSDB 3126
L001307
LS-565
METHYLPHENIDATE (SEE ALSO: METHYLPHENIDATE HYDROCHLORIDE, CAS 298-59-9, NTPNO 10266-R)
MPH
Meridil
Metadate
Metadate CD
Metadate ER
MethyPatch
Methyl (2-phenyl-2-(2-piperidyl)acetate)
Methyl alpha-phenyl-alpha-(2-piperidyl)acetate
Methyl alpha-phenyl-alpha-2-piperidinylacetate
Methyl phenidate
Methyl phenidyl acetate
 
Methyl phenidylacetate
Methylfenidan
Methylin
Methylin ER
Methylofenidan
Methylphen
Methylphenidan
Methylphenidate
Methylphenidate (USAN/INN)
Methylphenidate HCl
Methylphenidate Hydrochloride
Methylphenidate [INN:BAN]
Methylphenidate hydrochloride
Methylphenidatum
Methylphenidatum [INN-Latin]
Methylphenidylacetate hydrochloride
Methypatch
Metilfenidat hydrochloride
Metilfenidato
Metilfenidato [INN-Spanish]
Metilfenidato [Italian]
MolPort-001-779-620
NCI-C56280
PMS-Methylphenidate
Phenidylate
Plimasine
Quillivant XR
Riphenidate
Ritalin
Ritalin LA
Ritalin SR
Ritalin hydrochloride
Ritalin-SR
Ritaline
Ritcher Works
Ritcher works
Tsentedrin
UNII-207ZZ9QZ49
alpha-Phenyl-2-piperidineacetic acid methyl ester
alpha-Phenyl-alpha-(2-piperidyl)acetic acid methyl ester
d-methylphenidate HCl
methyl 2-phenyl-2-piperidin-2-ylacetate
methyl phenyl(piperidin-2-yl)acetate
methylphenidate
nchembio.2007.55-comp28
10
Doxorubicinapproved, investigationalPhase 3, Phase 2, Phase 1158223214-92-831703
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
14-hydroxydaunomycin
14-hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
ADM
ADR
Adriablastin
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin Semiquinone
Adriamycin semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (TN)
Adriblastina (hydrochloride salt)
Aerosolized Doxorubicin
BPBio1_000502
BRD-K92093830-003-04-3
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
CCRIS 739
CHEBI:28748
CHEMBL179
CID31703
Caelyx
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
DOX-SL
Doxil
Doxo
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin HCl
 
Doxorubicin Hydrochloride
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicine
Doxorubicine [INN-French]
Doxorubicinum
Doxorubicinum [INN-Latin]
EINECS 245-495-6
FI 106
Farmablastina (hydrochloride salt)
HMS2089H06
HSDB 3070
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
LMPK13050001
LS-1029
LS-165655
MLS000759533
Myocet
NCI-C01514
NChemBio.2007.10-comp13
NDC 38242-874
NIOSH/JT9100000
NSC 123127
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
TLC D-99
ThermoDox
Triferric doxorubicin
UNII-80168379AG
adiblastine (hydrochloride salt)
adr iablatina (hydrochloride salt)
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
adriblatina (hydrochloride salt)
doxorubicin
nchembio809-comp5
11
CarboplatinapprovedPhase 3, Phase 1, Phase 2188541575-94-410339178, 498142, 38904
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
Carbopaltin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
Cyclobutane-1,1-dicarboxylate
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
EINECS 255-446-0
EU-0100230
Ercar
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
IUPAC: Azane
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
 
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
LS-117689
Lopac-C-2538
Lopac0_000230
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NINDS_000892
NSC 201345
NSC 241240
NSC-241240
NSC201345
NSC241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, {diammine[1,1-cyclobut
S1215_Selleck
SPBio_000716
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
Spectrum_001529
UNII-BG3F62OND5
azanide
carboplatin
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
cyclobutane-1,1-dicarboxylic acid
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
platinum(2+)
12
Morphineapproved, investigationalPhase 385557-27-25288826
Synonyms:
(-)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(-)-Heroin hydrochloride
(-)-Morphine
(-)Morphine sulfate
(5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol
(5alpha,6alpha)-17-Methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL
(7R,7AS,12bs)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol
(−)-morphine
17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol
4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol
4-methyl-(13R,14S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol
47106-99-0
57-27-2
6211-15-0 (sulfate (2:1) (salt) pentahydrate)
64-31-3
64-31-3 (sulfate (2:1) (salt) anhydrous)
7,8-Didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol
7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
8053-16-5
85201-37-2
Apokyn
Astramorph PF
Avinza
BIDD:GT0147
C01516
CCRIS 5762
CHEBI:17303
CHEMBL70
CID5288826
Cube juice
D-(-)-Morphine
DB00295
DEA No. 9300
DepoDur
Depodur
Diacetylmorphine hydrochloride
Diamorphine hydrochloride
Dolcontin
Dreamer
Dulcontin
Duramorph
Duramorph PF
Duromorph
EINECS 200-320-2
Epimorph
HSDB 2134
Hard stuff
Heroin hydrochloride
Heroine hydrochloride
Hocus
Infumorph
 
Kadian
LS-91748
M-Eslon
M.O.S
MOI
MORPHINE SULFATE
MORPHINE, (5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL, MORPHIUM, MORPHIA, DOLCONTIN, DUROMORPH, MORPHINA, NEPENTHE
MS Contin
MS/L
MS/S
MSIR
Meconium
MolPort-003-849-273
Morfina
Morfina [Italian]
Morphia
Morphin
Morphin [German]
Morphina
Morphina [Italian]
Morphine
Morphine Extra-Forte
Morphine Forte
Morphine H.P
Morphine Sulfate
Morphine [BAN]
Morphinism
Morphinum
Morphitec
Morphium
Morpho
Moscontin
Ms Contin
Ms Emma
NSC11441
Nepenthe
O,O'-Diacetylmorphine hydrochloride
OMS Concentrate
Oramorph SR
Ospalivina
RMS
RMS Uniserts
Rescudose
Roxanol
Roxanol 100
Roxanol UD
SDZ 202-250
SDZ202-250
Statex
Statex Drops
Statex SR
UNII-76I7G6D29C
Unkie
l-Morphine
morphine
nchembio.317-comp1
nchembio.64-comp1
13
Octreotideapproved, investigationalPhase 319883150-76-9383414, 6400441
Synonyms:
(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-Aminobutyl)-19-((2-amino-3-phenylpropanoyl)amino)-16-benzyl-7-(1-hydroxyethyl)-N-(2-hydroxy-1-(hydroxymethyl)propyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaa
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
79517-01-4 (acetate salt)
83150-76-9
AC1L1GVU
AC1L8LCD
AC1L9M4X
C07306
C5H12O2.C4H10
CHEBI:427278
CHEBI:611465
CHEMBL1680
CID383414
CID448601
CID54374
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide
D00442
DRG-0115
HMS2090C09
HS-2020
L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide, (R-(R*
L000453
 
LS-177735
LS-187135
Longastatin
NCGC00181796-01
NCI60_025753
Ocphyl
Octreotida
Octreotida [Spanish]
Octreotide
Octreotide (USAN/INN)
Octreotide Acetate
Octreotide Acetate Salt
Octreotide [USAN:INN:BAN]
Octreotide acetate
Octreotide-LAR
Octreotidum
Octreotidum [Latin]
Octrotide
SAN 201-995
SM 201-995
SMS 201-995
SMS-201-995
Sandostatin
Sandostatine
Sandoz 201-995
UNII-RWM8CCW8GP
nchembio.184-comp3
zacycloicosane-4-carboxamide acetate
14
CyproheptadineapprovedPhase 315129-03-32913
Synonyms:
1-Methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine
1-Methyl-4-(5H-dibenzo(a,d)cycloheptenylidene)piperidine
1-methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine
129-03-3
4-(5-Dibenzo(a,D)cyclohepten-5-ylidine)-1-methylpiperidine
4-(5-Dibenzo(a,d)cyclohepten-5-ylidine)-1-methylpiperidine
4-(5H-Dibenzo(a,D)cyclohepten-5-ylidene)-1-methylpiperidine
4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidene
4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidine
4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine
4-(5H-dibenzo[a,d][7]annulen-5-ylidene)-1-methylpiperidine
4-Dibenzo[a,D]cyclohepten-5-ylidene-1-methyl-piperidine
41354-29-4
5-(1-Methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene
5-(1-methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene
5-20-08-00500 (Beilstein Handbook Reference)
AC1L1ER8
AKOS004119847
Axoprol
BIDD:GT0324
BPBio1_000096
BPBio1_000155
BRD-K28143534-001-01-4
BRD-K28143534-003-03-6
BRN 1685976
BSPBio_000086
Biomol-NT_000131
C06935
CAS-969-33-5
CCRIS 5232
CHEBI:4046
CHEMBL516
CID2913
CYPROHEPTADINE
Ciproheptadina
Ciproheptadina [INN-Spanish]
Ciprovit
Ciprovit (TN)
Cypoheptadine
Cyproheptadiene
Cyproheptadin
Cyproheptadine
Cyproheptadine (INN)
 
Cyproheptadine Hcl
Cyproheptadine Hydrochloride
Cyproheptadine [INN:BAN]
Cyproheptadinum
Cyproheptadinum [INN-Latin]
D07765
DB00434
Dibenzosuberonone/Cyproheptadine
Dihexazin
Dronactin
EINECS 204-928-9
Eiproheptadine
Glutodina
HMS2090P20
HSDB 3048
L001016
LS-114933
Lopac-C-6022
Lopac0_000246
MK 141
MolPort-002-507-777
NCGC00015252-01
NCGC00015252-02
NCGC00015252-03
NCGC00015252-09
NCGC00024293-02
NCGC00024293-04
NCGC00024293-05
Oprea1_498140
PDSP1_001229
PDSP2_001213
Periactin
Periactine
Periactinol
Prestwick0_000103
Prestwick1_000103
Prestwick2_000103
Prestwick3_000103
SPBio_002025
STK802098
Tocris-0996
UNII-2YHB6175DO
Viternum
nchembio.559-comp10
15
Histamine PhosphateapprovedPhase 390651-74-165513
Synonyms:
1H-Imidazole-4-ethanamine, phosphate (1:2)
2-Imidazol-4-ylethylamine orthophosphoric acid (1:2)
4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate)
4-(2-Aminoethyl)imidazole di-acid phosphate
4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate
51-74-1
53623-99-7
74-56-6
AC1L23E4
CID65513
D04445
DB00667
EINECS 200-118-4
 
H0147
Histamine Positive Skin Test Control
Histamine Positive skin test control
Histamine acid phosphate
Histamine biphosphate
Histamine dihydrogen phosphate
Histamine diphosphate
Histamine phosphate (1:2)
Histamine phosphate (TN)
Histamine phosphate (USP)
Histamine phosphate [USP]
Histamine positive
Histaminum
LS-78569
UNII-QWB37T4WZZ
16
DoxilApproved June 1999Phase 3, Phase 2, Phase 1158231703
Synonyms:
Dox-SL
Doxil
 
Evacet
LipoDox
Pegylated Liposomal Doxorubicin Hydrochloride
liposomal doxorubicin
17
Docetaxelapproved, investigational, Approved May 1996Phase 3, Phase 2, Phase 11844114977-28-5148124, 9877265
Synonyms:
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate
(2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
01885_FLUKA
114977-28-5
4-(Acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
AC-383
AC1L3WHJ
ANX-514
BIND-014
C11231
CHEBI:4672
CHEMBL92
CID148124
D07866
DB01248
Docefrez
Docetaxel
Docetaxel (INN)
Docetaxel anhydrous
Docetaxel, Trihydrate
EmDOC
 
HMS2089K08
InChI=1/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,5
MolPort-003-847-005
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-Boc-10-deacetyl taxol
NSC-628503
PSMA-targeted docetaxel nanoparticle
RP-56976
SDP-014
TXL
Taxotere
Taxotere (TN)
Taxotere(R)
XRP-6976L
docetaxel
docetaxel 114977-28-5
nchembio.188-comp8
nchembio.2007.34-comp7
nchembio.573-comp11
nchembio853-comp8
18Adjuvants, ImmunologicPhase 3, Phase 2, Phase 11783
19Central Nervous System DepressantsPhase 310016
20Anesthetics, GeneralPhase 32274
21Anesthetics, IntravenousPhase 31943
22Liver ExtractsPhase 3, Phase 1, Phase 23572
23pancreatic polypeptidePhase 320
24Topoisomerase InhibitorsPhase 3, Phase 2, Phase 14081
25Gastrointestinal AgentsPhase 3, Phase 26401
26Antineoplastic Agents, HormonalPhase 3, Phase 24256
27Analgesics, OpioidPhase 32304
28Antibiotics, AntitubercularPhase 3, Phase 2, Phase 15971
29Peripheral Nervous System AgentsPhase 3, Phase 2, Phase 118510
30Anti-Bacterial AgentsPhase 3, Phase 2, Phase 19140
31NarcoticsPhase 32709
32AnestheticsPhase 3, Phase 27385
33AnalgesicsPhase 3, Phase 19358
34Antimitotic AgentsPhase 3, Phase 2, Phase 14296
35Endothelial Growth FactorsPhase 3, Phase 2, Phase 1328
36Immunoglobulin GPhase 3, Phase 2, Phase 1146
37ImmunoglobulinsPhase 3, Phase 2, Phase 14477
38Antimetabolites, AntineoplasticPhase 3, Phase 2, Phase 15770
39AntimetabolitesPhase 3, Phase 2, Phase 19454
40Angiogenesis Modulating AgentsPhase 3, Phase 2, Phase 13611
41Angiogenesis InhibitorsPhase 3, Phase 2, Phase 13688
42AntibodiesPhase 3, Phase 2, Phase 14477
43Antibodies, MonoclonalPhase 3, Phase 2, Phase 12413
44Anti-Infective AgentsPhase 3, Phase 2, Phase 117220
45Immunologic FactorsPhase 3, Phase 2, Phase 118483
46Antiviral AgentsPhase 3, Phase 2, Phase 18071
47
MesnaPhase 3, Phase 2, Phase 12433375-50-6598
Synonyms:
2-Mercaptoethanesulfonate
2-Mercaptoethanesulfonic acid
 
CoM
Coenzyme M
HS-CoM
48Albumin-Bound PaclitaxelPhase 3, Phase 2, Phase 12621
49Immunosuppressive AgentsPhase 3, Phase 2, Phase 110422
50Antineoplastic Agents, PhytogenicPhase 3, Phase 2, Phase 14294

Interventional clinical trials:

(show top 50)    (show all 169)
idNameStatusNCT IDPhase
1Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the UterusCompletedNCT00002706Phase 3
2Radiation Therapy or No Further Treatment Following Surgery in Treating Patients With Cancer of the UterusCompletedNCT00002459Phase 3
3Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine LeiomyosarcomaCompletedNCT01012297Phase 3
4Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the UterusCompletedNCT00002546Phase 3
5Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the UterusCompletedNCT00003128Phase 3
6Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3
7Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue SarcomaCompletedNCT00002641Phase 3
8Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue SarcomaCompletedNCT00002764Phase 3
9Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue SarcomaCompletedNCT00003212Phase 3
10E-MOSAIC Electronic Tool to Monitor SymptomsCompletedNCT00477919Phase 3
11Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the PelvisCompletedNCT00033605Phase 3
12The Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine SarcomasRecruitingNCT00162721Phase 3
13Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by SurgeryRecruitingNCT01533207Phase 3
14Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic CancerRecruitingNCT01087268Phase 3
15Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity CancerActive, not recruitingNCT00954174Phase 3
16Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal SymptomsActive, not recruitingNCT01376349Phase 3
17Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for CancerTerminatedNCT01132547Phase 3
18Chemotherapy in Treating Patients With Sarcoma of the UterusCompletedNCT00005643Phase 2
19Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent SarcomaCompletedNCT00245102Phase 2
20AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue SarcomaCompletedNCT00659360Phase 2
21Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue SarcomaCompletedNCT00390234Phase 2
22Sorafenib in Treating Patients With Advanced or Recurrent Uterine CancerCompletedNCT00238121Phase 2
23Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By SurgeryCompletedNCT01553539Phase 2
24Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological MalignanciesCompletedNCT01079832Phase 2
25Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic SarcomaCompletedNCT01154452Phase 1, Phase 2
26Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine CancerCompletedNCT00075400Phase 2
27Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the UterusCompletedNCT00378911Phase 2
28Thalidomide in Treating Patients With Gynecologic SarcomasCompletedNCT00006005Phase 2
29Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic CancerCompletedNCT00032162Phase 1, Phase 2
30Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine LeiomyosarcomaCompletedNCT00101127Phase 2
31Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the UterusCompletedNCT00379145Phase 2
32Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine CancerCompletedNCT00112489Phase 2
33Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent SarcomasCompletedNCT00474994Phase 2
34Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue SarcomaCompletedNCT00053794Phase 2
35Chemotherapy in Treating Patients With Advanced SarcomaCompletedNCT00002526Phase 2
36Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue SarcomaCompletedNCT00003939Phase 2
37Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive TractCompletedNCT00003334Phase 2
38Exatecan Mesylate in Treating Patients With Advanced Soft Tissue SarcomaCompletedNCT00041236Phase 2
39Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue SarcomaCompletedNCT00004066Phase 2
40Dolastatin 10 in Treating Patients With Recurrent or Metastatic Soft Tissue SarcomaCompletedNCT00003778Phase 2
41BI 2536 in Treating Patients With Recurrent or Metastatic Solid TumorsCompletedNCT00526149Phase 2
42Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine CancerCompletedNCT01247571Phase 2
43Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine CancerCompletedNCT00114218Phase 2
44Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the UterusCompletedNCT00025506Phase 2
45Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic CancerCompletedNCT00381888Phase 2
46Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the UterusCompletedNCT00025220Phase 2
47Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the UterusCompletedNCT00031629Phase 2
48Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal TumorsCompletedNCT00815945Phase 2
49STI571 in Treating Patients With Recurrent or Refractory Soft Tissue SarcomaCompletedNCT00006357Phase 1, Phase 2
50Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal TumorsCompletedNCT00025441Phase 2

Search NIH Clinical Center for Uterine Sarcoma

Genetic Tests for Uterine Sarcoma

About this section

Anatomical Context for Uterine Sarcoma

About this section

MalaCards organs/tissues related to Uterine Sarcoma:

33
Uterus, Breast, Smooth muscle, Brain, Prostate, T cells, Lung

Animal Models for Uterine Sarcoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Uterine Sarcoma:

38 (show all 17)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00020069.1CDK2, ESR1, KIT, MDM2, SMARCB1, WT1
2MP:00053818.4ABCB1, CYP19A1, ESR1, KIT, MDM2, PDGFRB
3MP:00053808.2CDK2, ESR1, KIT, MB, MDM2, PDGFRB
4MP:00053798.1ABCB1, CDK2, CYP19A1, DCK, ESR1, KIT
5MP:00053898.1ABCB1, CDK2, CYP19A1, ESR1, KIT, MDM2
6MP:00053707.9ABCB1, CDK2, CYP19A1, ESR1, KIT, MDM2
7MP:00028737.7CYP19A1, DCK, ESR1, KIT, MDM2, MVP
8MP:00053697.4CDK2, CYP19A1, DES, ESR1, KIT, MB
9MP:00053787.2ABCB1, CDK2, CYP19A1, ESR1, KIT, MB
10MP:00107687.1ABCB1, ABCC1, CDK2, DES, ESR1, KIT
11MP:00053847.0CDK2, CYP19A1, DCK, DES, ESR1, KIT
12MP:00053856.3ABCB1, CDK2, CYP19A1, DES, ESR1, KIT
13MP:00053876.0ABCB1, ABCC1, CDK2, CYP19A1, DCK, ESR1
14MP:00053975.7ABCB1, ABCC1, CDK2, CYP19A1, DCK, ESR1
15MP:00053765.6ABCB1, ABCC1, CDK2, CYP19A1, DES, ESR1

Publications for Uterine Sarcoma

About this section

Articles related to Uterine Sarcoma:

(show top 50)    (show all 249)
idTitleAuthorsYear
1
Anesthetic Management of a Parturient with PHACE Syndrome for Cesarean Delivery. (26576049)
2015
2
Striated muscle fiber size, composition and capillary density in diabetes in relation to neuropathy and muscle strength. (24397623)
2014
3
Metabotropic glutamate receptor-1 contributes to progression in triple negative breast cancer. (24404125)
2014
4
Hypothesis: amenorrhea-inducing contraception may reduce HIV acquisition risk. (25282162)
2014
5
Clinical features of ATRX or DAXX mutated neuroblastoma. (25487495)
2014
6
Urinary concentration of cytokines in children with acute pyelonephritis. (23389820)
2013
7
When do essential tremor patients develop head tremor? Influences of age and duration and evidence of a biological clock. (23860504)
2013
8
Mutations in genes encoding the cadherin receptor-ligand pair DCHS1 and FAT4 disrupt cerebral cortical development. (24056717)
2013
9
Association between vitamin D receptor gene polymorphisms and bone mineral density in Chinese women. (22193625)
2012
10
Black Tea Polyphenols Reverse Epithelial-to-Mesenchymal Transition and Suppress Cancer Invasion and Proteases in Human Oral Cancer Cells. (22827697)
2012
11
The cost-effectiveness of tailored, postal feedback on general practitioners' prescribing of pharmacotherapies for alcohol dependence. (22361211)
2012
12
Challenges of the oral cancer burden in India. (23093961)
2012
13
Solution NMR structure of MED25(391-543) comprising the activator-interacting domain (ACID) of human mediator subunit 25. (21785987)
2011
14
WITHDRAWN: Psychological interventions for non-ulcer dyspepsia. (21328255)
2011
15
Transmembrane helix 1 contributes to substrate translocation and protein stability of bile acid transporter SLC10A2. (21646357)
2011
16
Learning discloses abnormal structural and functional plasticity at hippocampal synapses in the APP23 mouse model of Alzheimer's disease. (20404004)
2010
17
Prediction model for knee osteoarthritis based on genetic and clinical information. (20939878)
2010
18
A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia. (20441726)
2010
19
The impact of parenthood on alcohol consumption trajectories: variations as a function of timing of parenthood, familial alcoholism, and gender. (19338703)
2009
20
TAPP2 links phosphoinositide 3-kinase signaling to B-cell adhesion through interaction with the cytoskeletal protein utrophin: expression of a novel cell adhesion-promoting complex in B-cell leukemia. (19786618)
2009
21
Late (> 5 years) regional lymph node metastasis of oral squamous cell carcinoma (SCC), proven by p53 mutation analysis. (18554920)
2008
22
Contribution of the alcohol dehydrogenase-1B genotype and oral microorganisms to high salivary acetaldehyde concentrations in Japanese alcoholic men. (17471563)
2007
23
Overexpression of SOCS-2 and SOCS-3 genes reverses erythroid overgrowth and IGF-I hypersensitivity of primary polycythemia vera (PV) cells. (17325857)
2007
24
Mitochondrial POLG mutation, mtDNA depletion, and cardiomyopathy. (17486695)
2007
25
Melanocortin receptor ligands: new horizons for skin biology and clinical dermatology. (16912693)
2006
26
Expression of cyclooxygenase-2 in colorectal adenocarcinoma is associated with p53 accumulation and hdm2 overexpression. (15921850)
2006
27
Genetic susceptibility to rheumatic heart disease and streptococcal pharyngitis: association with HLA-DR alleles. (17026463)
2006
28
Dysautonomia and ventricular dysfunction in the indeterminate form of Chagas disease. (16376440)
2006
29
Expression pattern of telomerase reverse transcriptase in rectal carcinoma predicts tumor radiosensitivity, local recurrence and disease-free survival. (16001613)
2005
30
Oral pathology quiz #49. Case number 1. Florid cemento-osseous dysplasia. (16433301)
2005
31
Bone morphogenic protein-7 inhibits monocyte-stimulated TGF-beta1 generation in renal proximal tubular epithelial cells. (15574511)
2005
32
Increased activity of plasma and tissue kallikreins, plasma kininase II and salivary kallikrein in pemphigus foliaceus (fogo selvagem). (15840094)
2005
33
Expression of cyclooxygenase-1 and -2 and clinicopathologic features of colorectal cancer in northern Thailand. (15075004)
2004
34
Leptin interferes with the effects of the antiestrogen ICI 182,780 in MCF-7 breast cancer cells. (15475434)
2004
35
SNP S1103Y in the cardiac sodium channel gene SCN5A is associated with cardiac arrhythmias and sudden death in a white family. (12471205)
2002
36
Common origin and evolution of glycosyltransferases using Dol-P- monosaccharides as donor substrate. (12200473)
2002
37
Adult-onset primary open-angle glaucoma caused by mutations in optineurin. (11834836)
2002
38
Crystal structure of a model branchpoint-U2 snRNA duplex containing bulged adenosines. (11350032)
2001
39
Relationship between the anti-metastatic effect of UFT and in vitro chemosensitivity to 5-FU in metastatic tumors from orthotopic implanted colon cancer in nude rats]. (11383214)
2001
40
pp60(cSrc) is a caspase-3 substrate and Is essential for the transformed phenotype of A431 cells. (10775506)
2000
41
Characteristic MR lesion pattern and correlation of T1 and T2 lesion volume with neurologic and neuropsychological findings in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). (9974062)
1999
42
Fine-structure deletion mapping of 10q22-24 identifies regions of loss of heterozygosity and suggests that sporadic follicular thyroid adenomas and follicular thyroid carcinomas develop along distinct neoplastic pathways. (10534767)
1999
43
Molecular characterization of mouse Pneumocystis carinii surface glycoprotein A. (9679195)
1998
44
Erythrocyte hyperaggregation and thrombogenic dysfibrinogenemia. (9741663)
1998
45
Traumatic aortic incompetence associated with transection of the thoracic aorta. (8635344)
1996
46
Human cell mutagenicity of mono- and dinitropyrenes in metabolically competent MCL-5 cells. (7523917)
1994
47
Facioscapulohumeral muscular dystrophy defect identified. (1363882)
1992
48
Extracellular sequestration and release of fibroblast growth factor: a regulatory mechanism? (1926336)
1991
49
Semiconductor diode laser photocoagulation in retinal vascular disease. (2255529)
1990
50
Turnover of autologous alpha 1-antitrypsin in a patient with congenital analbuminemia. (6603561)
1983

Variations for Uterine Sarcoma

About this section

Expression for genes affiliated with Uterine Sarcoma

About this section
Search GEO for disease gene expression data for Uterine Sarcoma.

Pathways for genes affiliated with Uterine Sarcoma

About this section

GO Terms for genes affiliated with Uterine Sarcoma

About this section

Biological processes related to Uterine Sarcoma according to GeneCards Suite gene sharing:

(show all 7)
idNameGO IDScoreTop Affiliating Genes
1metanephric S-shaped body morphogenesisGO:007228410.3PDGFRB, WT1
2metanephric mesenchyme developmentGO:007207510.1PDGFRB, WT1
3positive regulation of phosphatidylinositol 3-kinase activityGO:00435529.7KIT, PDGFRB
4cellular response to estrogen stimulusGO:00713919.7ESR1, MDM2
5positive regulation of phospholipase C activityGO:00108639.6ESR1, KIT, PDGFRB
6phosphatidylinositol-mediated signalingGO:00480159.5KIT, MDM2, PDGFRB
7response to toxic substanceGO:00096369.5CDK2, MDM2, PDGFRB

Sources for Uterine Sarcoma

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet